Market Share of Immune Checkpoint Inhibitors Industry
The immune checkpoint inhibitors market is moderately competitive and consists of several major players. Some of the companies are expanding their market position by adopting various strategies such as acquisitions and mergers, and research collaboration, while others are investing in clinical trials to extend the treatment of other indications with the existing drugs to address the unmet challenges of the disease burden driving the market share. A few of the major players currently dominating the industry in terms of revenue are BristolMyers Squibb Company, AstraZeneca PLC, F. Hoffmann-La Roche AG, Regeneron Pharmaceuticals Inc., and Merck & Co. Inc.
Immune Checkpoint Inhibitors Market Leaders
Bristol Myers Squibb Company
Regeneron Pharmaceuticals Inc
AstraZeneca plc
F. Hoffmann-La Roche AG
Merck & Co Inc
*Disclaimer: Major Players sorted in no particular order
